Clinical Research
Opportunities
Penn Medicine is conducting studies to develop new ways to prevent, diagnose, and treat disease. You might be eligible to participate
Get Started
Clinical Research Opportunities
Penn Medicine is conducting studies to develop new ways to prevent, diagnose, and treat disease. You might be eligible to participate
Penn Medicine is conducting studies to develop new ways to prevent, diagnose, and treat disease. You might be eligible to participate
Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.
Search by keywords
Browse by Condition or Investigator
Browse all TrialsFeatured studies
UPCC 31920 Penn Medicine BioBank
The Penn Medicine Biobank is collecting and storing biological specimens such as blood, as well as health information from volunteers. These samples and this information allow researchers to use them for research studies including but not limited to COVID-19, cancer, diabetes, and heart disease.
The GRoceries Aimed at Increasing Nutrition Study (GRAIN Study)
We are looking for adults ages 45-70 to take part in an 18-week study about people‘s online grocery shopping habits. You’ll get a free Walmart+ membership for your grocery deliveries and receive $10 back on all weekly orders over $35. You may earn over $200 in total for completing study …
Adult Virome Study
Did you know that all of us, including all healthy people, have viruses in our bodies that do not make us sick but actually may contribute to health? Researchers are exploring the viruses that exist in people that are not currently sick in order to understand their role in human …
Click & Pick Study
The University of Pennsylvania is conducting a 6-week research study to learn about your experience using online grocery stores and online restaurant ordering applications.
MethaLoad Dose-Finding Study
Do you use fentanyl and want to start methadone? You may qualify for a paid research study at Penn Medicine. Methadone is usually started at a low dose that goes up slowly over days to weeks. Some people stay in withdrawal while their dose catches up. This study is testing …
Recently Added/Updated trials
UPCC 03226 RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
UPCC 68425 An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent and in Combination with Other Anti-lymphoma Agents, in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas
In this research study, a new product called TLN-121 will be tested with or without a new product called TLN-254. TLN-121 and TLN-254 are being studied to treat non-Hodgkin lymphoma that has relapsed (cancer that has come back after it had been treated and was under control) or refractory (cancer that did not respond to or kept growing with treatment).
UPCC 07526: ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 > 50%
The purpose of this research is to learn whether the investigational drug, pumitamig, works to treat a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to nearby tissues and/or outside of the lung.
UPCC 44825 A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FR-high and AZD5335 Versus Investigators Choice Chemotherapy in FR-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)
This research study is designed to learn more about the safety and effectiveness of AZD5335, given to individuals who have been diagnosed with platinum-resistant ovarian cancer, by comparing AZD5335 to standard of care therapies.
AUR-200-2024-02
Double-blind trial of Aritinercept (2:1 treatment vs placebo ratio) subcutaneous injection for the treatment of gMG, followed by open-label treatment period for all participants. Dosing frequency every 4 weeks.
Volunteer Sign-Up
If you don’t see a trial that fits your needs, consider joining our research volunteer registry. By signing up, you’ll be notified if a study matches your background and health profile.
Virtual Studies
Also called Online or Decentralized studies. Some may be a mix of remote and in-person visits.
Penn Medicine experts answer questions from patient advocates and share groundbreaking medical developments happening at the University of Pennsylvania.
Please choose between Voice or SMS based delivery of verification code
or